Irinotecan induces small ubiquitin-like modifier (SUMO)-1 conjugation to topoisomerase-I, leading to enhanced sensitivity to irinotecan. In this study, we genotyped SUMO1 and UBC9 polymorphisms in 147 non-small-cell lung cancer (NSCLC) treated with irinotecan chemotherapy to investigate the association between genotypes and tumor response rate. Immunohistochemistry for SUMO1 and UBC9 was performed in 42 tumor samples and correlated with genotypes. The UBC9 10920CG genotype was associated with significantly higher response rate than the C/C genotype (81 vs 37%, P ¼ 0.0002). This predictive effect on tumor response was also seen in multivariate analysis (odds ratio ¼ 8.5, P ¼ 0.003). Moreover, tumors arising from the UBC9 10920CG genotype were associated with higher prevalence of SUMO1 overexpression compared with those with CC genotype (78 vs 31%, P ¼ 0.021). This finding suggests that the UBC9 10920CG genotype enhances sensitivity to irinotecan chemotherapy in advanced NSCLC through upregulation of SUMO1 in tumor cells.
Introduction
Irinotecan is a camptothecin (CPT) analogue and specifically targets DNA topoisomerase-I (TOP1). 1, 2 Although irinotecan has proved to be effective in lung cancer, resistance is still a critical clinical problem. 3, 4 As TOP1 is the unique target of irinotecan, reduction in TOP1 amount or activity can influence the sensitivity to irinotecan. [5] [6] [7] Indeed, there is good correlation between sensitivity to CPT and TOP1 levels for certain tumor cell lines. 5, 7 TOP1 is ubiquitinated and degraded following CPT treatment. Moreover, tumor cells deficient in CPT-induced TOP1 downregulation were found to be more sensitive to CPT, implicating TOP1 levels could be an important determinant for CPT sensitivity. 8, 9 Human SUMO (small ubiquitin-like modifier)-1 is an 11 kDa protein that shares 18% sequence homology with ubiquitin. Like ubiquitination, sumoylation is mediated by a specific set of enzymes to form a covalent bond at a lysine residue of target proteins. 10 Although several E2 enzymes have been identified for ubiquitination, UBC9 is the sole E2-conjugating enzyme identified for sumoylation. 11 Although sumoylation is similar to ubiquitination in structure, conjugation process and attachment to target proteins, the biologic consequences are different. Unlike ubiquitination that normally targets proteins degradation through proteasome pathway, sumoylation has been implicated in the regulation of protein stability, protein-protein interactions, transcriptional activity and subcellular localization. [12] [13] [14] SUMO1 has shown to compete with ubiquitin for the conjugation of the same protein on the same site. As a result, the protein can be stabilized from ubiquitin-proteasome-mediated degradation. 12 Of interest, TOP1 is also modified by SUMO1 following CPT treatment. [12] [13] [14] [15] [16] [17] Because both sumoylation and ubiquitination take place at the same lysine residues, TOP1 sumoylation may inhibit TOP1 ubiquitination and degradation in response to CPT. Recently an in vitro study showed that sumoylation of TOP1 enhanced cleavable complex formation and apoptosis induced by CPT. 12 In addition, TOP1 sumoylation was completely abolished by expression of dominantnegative UBC9, suggesting that TOP1 sumoylation is dependent on UBC9. Given the possibility that SUMO1 and UBC9 may affect the responsiveness to irinotecan, we analyzed the association of SUMO1 and UBC9 expression and polymorphisms with clinical outcome in non-small-cell lung cancer (NSCLC) treated with irinotecan-based chemotherapy. Because the relationship between genetic variations of metabolizing enzymes or transporters of irinotecan and irinotecan-related severe toxicities or tumor response has been widely reported, [18] [19] [20] [21] [22] [23] we additionally examined these polymorphisms and analyzed the association with SUMO1 and UBC9 polymorphisms in this study.
Materials and methods

Study population
Patient population (n ¼ 147) consisted of Korean subjects that had been diagnosed for advanced NSCLC (stage IIIB with pleural effusion or stage IV) between 2002 and 2006. All patients received irinotecan and cisplatin (IP) chemotherapy as a first-line therapy and participated in at least one clinical trial while being treated. These protocols permitted blood and/or tissue collections before chemotherapy start. All patients signed informed consents for genotypic analysis. This study was conducted under the approval of the ethical review boards and the guidelines for good clinical practice.
Among 147 patients, 107 were previously evaluated for UGT1A1*6, UGT1A1*28, UGT1A9*22, ABCC2, ABCG2 and SLCO1B1 polymorphisms and the findings were published elsewhere. 20, 24, 25 We used the known genotype information or additional new data of these polymorphisms to analyze the association with SUMO1 and UBC9 polymorphisms. Genomic DNA was extracted from blood using a PUREGENE DNA kit (Gentra Inc., Minneapolis, MN, USA). Genotypes were assayed by single-base primer extension assay using an ABI PRISM SNaPShot Multiplex kit and ABI Prism 3730xl DNA analyzer (ABI, Foster City, CA, USA). The detailed methods have been described previously. 26, 27 Briefly, the genomic DNA flanking the SNPs was amplified with PCR using forward and reverse primer pairs and standard PCR reagents in 10 ml reaction volume, containing 10 ng of genomic DNA, 0.5 pM of each oligonucleotide primer, 1 ml of 10Â PCR Gold buffer, 250 mM dNTP, 3 Final reaction samples (1 ml) that contained the extension products were added to 9 ml of Hi-Di formamide (ABI). The mixture was incubated at 95 1C for 5 min, followed by 5 min on ice and then this was analyzed by electrophoresis in ABI Prism 3730xl DNA analyzer. The results were analyzed using GeneScan analysis software (ABI). The primer sequences are summarized in Table 1 .
Chemotherapy regimens
Immunohistochemical staining
Immunohistochemical (IHC) staining for SUMO1 and UBC9 was performed using anti-mouse SUMO1 monoclonal (sc-5308, 1:400) and anti-goat UBC9 polyclonal (sc-5231, 1:400) antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and the detailed procedure was described elsewhere. 21 The extent of staining was scored on a semiquantitative scale of 0-4: 0, no detectable staining; 1, o10% scattered cells; 2, 10-25%; 3, 425% but o50%; 4, homogeneous staining in 450% of cells. The intensity of staining was scored: 0, no detectable staining; 1, weakly stained nuclei; 2, moderately stained nuclei; 3, strongly stained nuclei. Final scores were derived from multiplication of extent by intensity and score exceeding 9 (that is, tumors with a staining intensity score of 3 and with 25% or more positive nuclei) were deemed to be SUMO1 or UBC9 overexpression.
Statistical analysis w
2 -test or Fisher's exact test was used to compare differences in proportions between groups for the categorical variables. Logistic regression was used as a multivariate method to ascertain which genotype independently predicted response. Model selection included performance status, gender, age, smoking status and genotype information. A stepwise selection procedure was used and the entry criteria were set at Po0.1. Kaplan-Meier estimates and the log-rank tests were used in the univariate analysis of PFS and OS. Statistical analyses were performed using SPSS (Chicago, IL, USA) and twosided P-value o0.05 were considered significant. (Table 3) . Patients with the UBC9 10920C/G genotype had a significantly higher ORR than those with homozygous C/C (81 vs 37%, P ¼ 0.0002). Because previously we found that ABCC2 À24C4T and 3972C4T polymorphisms were associated with tumor response rate, we included the known genotype information of these polymorphisms in a multivariate analysis (n ¼ 107). 24 In a multivariate logistic analysis using the associated factors with Po0.1 as predictive variables, only the UBC9 10920C4G variant maintained its predictive value on the response rate to IP chemotherapy (OR ¼ 8.5, 95% confidence interval (CI); 2.1-34.6, P ¼ 0.003).
Genotype and survival On 6 October 2008, the median follow-up period was 51.9 months (range, 21.3-73 months) and 136 deaths (92.5%) occurred. In the whole population, the median PFS time was 4.9 months (95% CI, 4.2-5.6 months) and the median OS time was 15.8 months (95% CI, 13.1-18.5 months).
With regard to PFS or OS, neither SUMO1 nor UBC9 polymorphisms showed statistical significance. PFS and OS were numerically increased in patients with the UBC9 10920CG genotype compared with those with CC genotype (5.5 vs 4.7 months for PFS; 15.9 vs 11.5 months for OS, respectively), but the difference did not reach a statistical significance (P ¼ 0.4 and 0.8, respectively). Abbreviations: CI, confidence interval; OR, odds ratio; RR, response rate (the proportion of the patients whose best response was complete or partial response among all assessable patients).
The difference in the total number of patients is due to the fact that not all samples yielded genotyping call.
SUMO1 and UBC9 expression and genotypes
Out of 147 patients participated, 42 tumor samples were available for IHC staining of SUMO1 and UBC9. The overexpression of SUMO1 and UBC9 was observed in 18 (43%) and 11 (26%) cases, respectively. In an effort to ascribe the definite phenotype of SUMO1 and UBC9 polymorphisms, we investigated the relationship between each genotype and protein expression (Table 4) . Tumors arising in the UBC9 10920C/G individuals had a higher prevalence of SUMO1 overexpression than those arising in homozygous wild-type individuals (78 vs 31%, P ¼ 0.021). No significant association was observed among other polymorphisms.
Genotype and toxicity
Because UGT1A1*6, UGT1A1*28 and UGT1A9*22 genotypes have been reported to be related with irinotecanrelated severe toxicities, [18] [19] [20] we further examined these polymorphisms in the whole-study population (n ¼ 147). There was no homozygous UGT1A1*28 in this population. Previously we also found that SLCO1B1 521T4C polymorphism was associated with grade 4 neutropenia, 25 thus we used the known genotype information of this polymorphism in this analysis (n ¼ 107).
Likewise the previously reported results, the UGT1A1*6/*6 and SLCO1B1 521TC or CC genotypes were associated with grade 4 neutropenia and the UGT1A9*22 9/9 and ABCC2 3972CC genotypes were associated with grade 3 diarrhea (Table 5) . Among SUMO1 and UBC9 polymorphisms, the SUMO1-150GA or AA genotypes and the UBC9 10920CG or GG genotypes showed a trend for grade 4 neutropenia (P ¼ 0.075) and grade 3 diarrhea (P ¼ 0.054), respectively. In a logistic regression model, using the associated factors (Po0.1) as predictive variables, the homozygous UGT1A1*6 and the SLCO1B1 521TT genotype were predictive for grade 4 neutropenia. The UGT1A9*22 9/9 and the ABCG2 34GA or AA genotypes were predictive for grade 3 diarrhea. None of SUMO1 or UGC9 polymorphisms was significantly predictive for irinotecan-related severe toxicities in a multivariate analysis.
Discussion
We first examined SUMO1 and UBC9, a key regulator of sumoylation pathway, expression as well as their polymorphisms as a predictive biomarker for IP chemotherapy in patients with advanced NSCLC. So far, most pharmacogenetic studies of irinotecan for predicting either toxicity or tumor response were mainly focused on metabolizing enzymes and transporters. Most consistent association has been shown for homozygous UGT1A1*28 with grade 4 neutropenia in Caucasian population, although its impact on neutropenia is highly dependent on irinotecan dose. 18, 19 Other genetic variations in UGT1A9, ABCB1, ABCC2, ABCG2 and SLCO1B1 also have been suggested to contribute to the variability of irinotecan pharmacokinetics and toxicity. [20] [21] [22] [23] [24] [25] Although there is a consistent evidence that increased AUC of SN38, the active metabolite of irinotecan, can cause increased risk of severe toxicities in patients receiving irinotecan therapy, data regarding tumor response of irinotecan-based therapy are contradicting. These findings suggest that systemic irinotecan levels may be different from intratumoral levels and the sensitivity to irinotecan in cancer cells may be different from normal cells.
As the molecular target of SN38, TOP1 is a plausible predictive marker for irinotecan chemotherapy. [5] [6] [7] [8] [9] As well as preclinical models, a recent clinical study has shown that high TOP1 expression in cancer cells was predictive for benefit from irinotecan chemotherapy in patients with advanced colorectal cancer. 28 Recently increasing evidence suggests that post-translation modification of TOP1 after irinotecan therapy may influence sensitivity to irinotecan therapy. 4 Several preclinical studies have shown that a ubiquitin/26S proteasome pathway is activated by CPT and this leads to the degradation of TOP1 in cells. 8, 9 Thus, if tumor cells are defective to irinotecan-induced TOP1 degradation, sensitivity to irinotecan would be increased. Because sumoylation has been implicated in the regulation of protein stability and activity, TOP1 sumoylation may inhibit TOP1 degradation and enhance sensitivity to irinotecan. 12 Recently we examined SUMO1 expression in 109 archival NSCLC and small-cell lung cancer (SCLC) tissues, which were obtained from patients treated with IP chemotherapy, and correlated with tumor response rate (data not shown). We found that SUMO1 overexpression was associated with tumor response to IP chemotherapy. Compared with nonresponders (stable or progressive disease), responders (complete or partial response) showed higher prevalence of SUMO1 overexpression (63% (47/75) vs 40% (12/30), respectively; P ¼ 0.034). Of interest, SUMO1 overexpression was more common in SCLC compared with NSCLC (64% (43/67) vs 43% (18/42), respectively; P ¼ 0.029), which supports the significant difference in response rate to IP chemotherapy between SCLC and NSCLC (92% (122/132) vs 43% (61/ 143), Po0.0001). In this study, we found that the UBC9 10920C4G variant was associated tumor response to IP chemotherapy in advanced NSCLC. Patients with the UBC9 10920CG genotype showed higher response rate to IP chemotherapy. We also found that this genotype was associated with higher prevalence of SUMO1 overexpression in cancer cells. These findings support the hypothesis that high expression of SUMO1 in lung cancer cells may increase TOP1 expression or activity in lung cancer cells, which may result in enhanced response to IP chemotherapy.
Increased expression of TOP1 also enhances sensitivity to cisplatin. A preclinical model showed that cisplatin-DNA adducts act as persistent TOP1 poisons, which is exacerbated in the presence of topotecan. 29 It supports the synergistic activity of platinum drugs with CPTs. Moreover, a recent clinical study has shown that TOP1 expression in cancer cells was predictive for response to oxaliplatin in patients with advanced colorectal cancer. 24 In this study, all patients received irinotecan and cisplatin combination chemotherapy. Therefore, SUMO1 overexpression in lung cancer cells may contribute to enhance sensitivity to cisplatin as well as irinotecan.
In addition to TOP1, nuclear factorkB (NF-kB) has also been attributed to develop resistance to irinotecan. 3, 4 Recently multiple experiments showed that irinotecan treatment can activate NF-kB, which suppresses the apoptotic cascade induced by irinotecan. 30 As a main substrate of IkB kinase complex, IkBa functions as an inhibitor of NF-kB transcription activity. As to IkBa, sumoylation competes with ubiquitination by targeting same lysine residue. SUMO-1-modified IkBa cannot be ubiquitinated and is resistant to proteasome-mediated degradation, which inhibits NF-kB-dependent transcription. 31 Therefore, SUMO1 overexpression in lung cancer cells may inhibit NF-kB activation through the stabilization of IkBa, which can enhance response to irinotecan therapy. In addition, SUMO1 is conjugated to p53 at the C terminus of p53 involving a specific lysine residue at position 386, which activates the transcriptional activity of wild-type p53. 32, 33 This effect of SUMO1 also seems to enhance response to IP chemotherapy. 1, 2 To our knowledge, this study provides the first demonstration that the UBC9 10920CG genotype, which is associated with SUMO1 overexpression, is predictive for favorable response to IP chemotherapy in patients with advanced NSCLC. Further larger scaled trials and functional studies would be necessary to confirm predictive effects of SUMO1 and UBC9 in lung cancer. Nevertheless, we provide another novel genetic possibility, which may contribute the sensitivity of irinotecan in patients with lung cancer. This finding would be helpful to further understand irinotecan pharmacogenetics and optimize the clinical use of irinotecan in patients with lung cancer.
